While TNP-ATP is a potent P2X receptor antagonist in isolated cells, its rapid breakdown by nucleotidases limits its utility in whole tissue experiments.
Answers are grounded in this paper and cite their sources.
May limit TNP-ATP utility in intact tissues; leaves open stable P2X antagonists for research.
P2X receptor activation by alpha,beta-meATP evoked inward currents in acutely dissociated rat mesenteric artery smooth muscle cells and contractions of whole artery rings. 2. The selective P2X1 and P2X3 receptor antagonist TNP-ATP inhibited P2X receptor mediated inward currents in response to 3 microM alpha,beta-meATP (an approximately EC90 concentration) with an IC50 of approximately 2 nM. This provides further evidence that the P2X receptor underlying membrane depolarisation associated with P2X receptor activation can be accounted for by the expression of P2X1 receptors. 3. TNP-ATP inhibited alpha,beta-meATP induced contractions with an IC50 of approximately 30 microM and had non-specific effects on smooth muscle contraction. 4. The reduced potency of TNP-ATP in whole tissue experiments probably reflects the breakdown of TNP-ATP by nucleotidases. Thus, TNP-ATP is of limited use in whole tissue experiments as a P2X receptor antagonist.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: